# Biomarker-based differentiation of pregnancy-associated thrombotic microangiopathies: A systematic review
> Andonotopo W.

URL kanonis: https://discover.unhas.ac.id/publications/pub_scopus_105055051495
Jurnal / Konferensi: Iraqi Journal of Hematology
Tahun terbit: 2026
DOI: https://doi.org/10.4103/ijh.ijh_85_26
ISSN: 20728069
Kuartil SJR: Q4
Citations: 0

## Authors
- Andonotopo W.

## Abstract
Pregnancy-associated thrombotic microangiopathies (TMAs), including hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome, preeclampsia, thrombotic thrombocytopenic purpura (TTP), and complement-mediated TMA/atypical hemolytic uremic syndrome (aHUS), remain among the most difficult conditions to distinguish during pregnancy and the postpartum period because they share overlapping clinical and laboratory manifestations despite fundamentally different pathogenic mechanisms and therapeutic strategies. This systematic review, conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines, synthesized current evidence on the diagnostic utility of ADAMTS13, complement-related biomarkers, and angiogenic markers for differentiating these disorders. A comprehensive search of major biomedical databases identified 948 records. Following duplicate removal, title and abstract screening, full-text eligibility assessment, and application of predefined inclusion criteria, 35 studies were included in a qualitative synthesis. Quantitative meta-analysis was not undertaken because of substantial clinical and methodological heterogeneity across study designs, patient populations, biomarker assays, diagnostic definitions, and reported outcomes. Across the available evidence, severe ADAMTS13 deficiency consistently emerged as the most reliable laboratory indicator of TTP, whereas persistent postpartum hemolysis accompanied by acute kidney injury strongly supported consideration of complement-mediated TMA/aHUS. HELLP syndrome and preeclampsia demonstrated partial overlap with complement activation and disturbances of the von Willebrand factor–ADAMTS13 axis, reflecting shared endothelial injury rather than identical disease mechanisms. Angiogenic biomarkers, particularly the soluble fms-like tyrosine kinase-1/placental growth factor ratio, provided valuable adjunctive information for identifying placental disease but were most informative when interpreted alongside serial laboratory changes and the evolving clinical course. Overall, the evidence supports an integrated biomarker-based diagnostic framework that combines clinical assessment with ADAMTS13 testing, complement evaluation, angiogenic biomarkers, and postpartum laboratory trajectories to facilitate earlier disease-specific diagnosis and management while reducing preventable maternal and fetal morbidity.

## Keywords
- Medicine
- HELLP syndrome
- Thrombotic thrombocytopenic purpura
- Thrombotic microangiopathy
- Preeclampsia
- Von Willebrand factor
- Atypical hemolytic uremic syndrome
- Biomarker
- Postpartum period
- Disease
- ADAMTS13
- Intensive care medicine
- Pregnancy
- Immunology
- Acute kidney injury
- Complement system
- Systematic review
- Haemolytic-uraemic syndrome
- Hemolysis
- Kidney disease
- Schistocyte
- Bioinformatics
- Internal medicine
- Eculizumab
- Antiphospholipid syndrome
- Hemolytic anemia
- Platelet
- Placental growth factor
- Etiology
- Autoantibody
- Clinical Practice
- Genetic testing
- Eclampsia
- Rare disease

---
Sumber: Discover Unhas — RIMS Universitas Hasanuddin.
Saat mengutip, gunakan DOI bila tersedia atau URL kanonis di atas.